Authors
Latest:
Dr. Jeffrey Weber on Potential Breakthrough "Cures" in MelanomaWeber says these treatments, such as ipilimumab plus nivolumab, or dabrafenib and trametinib, have seen marked improvements since 2009, and continue to become more important in the treatment paradigm of melanoma.
Latest:
Exploring Novel Ibrutinib Combinations in Clinical Trials for CLLJennifer A. Woymach, MD, provides background information on the AO41702 study, which evaluates targeted therapy ibrutinib or ibrutinib plus rituximab in elderly patients with previously untreated chronic lymphocytic leukemia.<br />
Latest:
Brown on Data From the Phase 3 ALPINE Trial of Zanubrutinib in R/R CLLJennifer R. Brown, MD, PhD, highlights the results from the phase 3 ALPINE study evaluating the treatment with zanubrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Latest:
Dr. Chan Discusses Cabozantinib for the Treatment of NETsJennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.
Latest:
Dual Targeting With an HDAC 6 Inhibitor and Bortezomib in LymphomaJennifer E. Amengual, MD, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
Latest:
Diagnosing G3 NETs and NECsJennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.
Latest:
Checkpoint Inhibitors Gain Traction in the Frontline Setting for Cancers of the EsophagusThis past year, 2020, will go down as a practice-changing one for the treatment of esophageal cancer, said Yelena Y. Janjigian, MD.
Latest:
For Advanced Heme Malignancies, CAR T Cells Overcome Exhaustion, Tumor EscapeProgress in the development of chimeric antigen receptor T-cell therapy and other cell-based therapies has led to new therapeutic options for advanced malignancies. CAR T-cell agents approved by the FDA in recent years include axicabtagene ciloleucel for diffuse large B-cell lymphoma and tisagenlecleucel for both DLBCL and acute lymphoblastic leukemia.
Latest:
Moving Forward: Examining the Evolving Role of Embolization in HCCDespite the widespread prevalence of hepatocellular carcinoma (HCC), effective treatment options for both primary and secondary liver tumors have remained elusive, as these tumors are difficult to manage, especially in cases where the tumor is unresectable.
Latest:
The Incidence of Thyroid Cancer Among Breast Cancer SurvivorsJennifer H. Kuo, MD, director, Thyroid Biopsy Program, Columbia University, discusses a study looking at the incidence of thyroid cancer among breast cancer survivors.
Latest:
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma CollaborationAmgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Latest:
Addressing the Role of PARP Inhibitors in Different Breast Cancer SettingsJennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.
Latest:
Promise Is Seen in Newer EGFR TKIs to Overcome Resistance in NSCLCAcquired resistance to tyrosine kinase inhibitors targeting <em>EGFR</em> mutations in patients with non–small cell lung cancer are leading to next-generation therapies equipped to circumvent the mutations that arise from initial treatment. A review of these mechanisms, and the latest agents being developed to address them, shows that the pipeline holds promise for the future.
Latest:
The Relationships of MRI Imaging Characteristics With RaceJennifer Montes, MD, NYU Langone Medical Center, discusses a recent study evaluating the relationship between race and breast cancer findings in magnetic resonance imaging (MRI) tests.
Latest:
Addition of Cetuximab to Chemoradiation in Esophageal Cancer Does Not Improve OSAdding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus.
Latest:
Addressing Unmet Needs for Patients with CLL on ZanubrutinibJennifer R. Brown, MD, PhD, discusses the unmet needs for patients with chronic lymphocytic leukemia that are treated with zanubrutinib.
Latest:
Effect of Anamorelin on Cachexia in Advanced NSCLCJennifer S. Temel, clinical director, Thoracic Oncology, Massachusetts General Hospital, discusses a phase III study that examined the impact of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.
Latest:
Cirmtuzumab Blocks Ovarian Cancer Metastasis in Preclinical StudyThe monoclonal antibody cirmtuzumab, currently in clinical trials to treat CLL, targets ROR1 on the surface of cancerous B cells, and the agent may have a wider reach in the treatment of ovarian and other cancers.
Latest:
Association Between Gut Microbiome and Responses in Melanoma Patients on Anti-PD-1 TherapyJennifer Wargo, MD, associate professor of Genomic Medicine and Surgical Oncology, discusses a study that looked at the association of the diversity and composition of the gut microbiome with responses and survival in metastatic melanoma patients on anti-PD-1 therapy.
Latest:
Pirtobrutinib as a Game Changer for Patients With CLLJennifer A. Woyach, MD, discusses how pirtobrutinib compares against other Bruton tyrosine kinase inhibitors and delves into the next steps for the agent in the CLL/SLL space.
Latest:
Dr. Jennifer Wu on Proliferations and Mutations in Colorectal CancerJennifer Wu, MD, discusses the issue of deficiencies in enzymes that fix mismatch repairs in colorectal cancer. Wu says targeting the cancer-specific enzymes which allow tumors to repair themselves could stop tumor growth in patients.
Latest:
Using Antibody-Mediated Neutralization of Soluble MIC to Enhance Response to CTLA-4 BlockadeJennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Latest:
Abemaciclib Combinations Demonstrate Long-Term Disease Control in HR+ Breast CancerIn a recent study, abemaciclib demonstrated clinical activity both alone and in combinations in women with HR+ metastatic breast cancer.
Latest:
Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPCJeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.
Latest:
Abramson Discusses Liso-Cel as a Transformative Therapy in LBCLJeremy Abramson, MD, discusses what the findings from the phase 3 TRANSFORM study of lisocabtagene maraleucel mean for patients with relapsed large B-cell lymphoma.
Latest:
PARP Inhibitors Offer Hope for Patients With Ovarian CancerMichael J. Birrer, MD, PhD, discusses the introduction of poly ADP-ribose polymerase inhibitors to the ovarian cancer treatment landscape.
Latest:
Dr. Jessica Frakes on Monitoring Recurrences in HPV-Positive Oropharyngeal Squamous Cell CarcinomaFrakes says the number of HPV-positive oropharyngeal cancer diagnoses year to year is growing, though the number of survivors is proportionate.
Latest:
Durvalumab Combined Chemotherapy Extends OS in Advanced Biliary Tract CancerTOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.
Latest:
Projecting Cancer Incidence in HIV-Positive Population in the US Through 2030Jessica Islam, MPH, a PhD student at the University of North Carolina at Chapel Hill Gillings School of Global Public Health, discusses research that projected cancer incidence in the HIV-positive population in the United States through 2030.
